Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. OnabotulinumtoxinA (Botox — Allergan Inc.) indication: chronic migraine. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC Final Recommendation; SR0345. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that onabotulinumtoxinA (OA) not be listed for the management of chronic migraine. Indexing Status Subject indexing assigned by CRD MeSH Botulinum Toxins, Type As; Migraine Disorders Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32015000214 Date abstract record published 06/03/2015 |